Clinical Trial

A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to assess Tacrolimus/Methotrexate/Ruxolitinib versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation
Protocol Amendment History 23 amendments
This ClinicalTrials.gov record has been amended 23 times since 2024-09-25; most recent amendment 2026-05-19.
Status change: Not Yet Recruiting → Recruiting 2025-03-06
Trial Details
NCT Number NCT06615050
Lead Sponsor Incyte Corporation
Collaborators: Blood and Marrow Transplant Clinical Trials Network, National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), National Cancer Institute (NCI)
Conditions Graft-versus-host Disease (GVHD)
Enrollment 572 participants
Start Date 2025-04-02
Primary Completion 2031-01-17 (estimated)
Study Completion 2031-01-17 (estimated)
Updated on ClinicalTrials.gov 2026-05-20